Newly Issued US Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates
Spotlight Innovation Inc. recently announced that US Patent No. 9,895,358, titled Combination Therapies for Treatment of Spinal Muscular Atrophy, has been issued to Indiana University Research and Technology Corp. and The Brigham and Women’s Hospital, Inc. The patent discloses compositions and methods for the treatment of spinal muscular atrophy (SMA), including STL-182 and related compounds, to which Spotlight Innovation holds an exclusive, worldwide commercial license.
The patent’s inventors include Dr. Elliot Androphy of the IU School of Medicine and Prof. Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women’s Hospital. A research collaboration between the inventors led to synthesis and early preclinical testing of STL-182. Dr. Androphy and Prof. Hodgetts are members of Spotlight Innovation’s Scientific Advisory Board.
Spotlight Innovation Inc. acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging, and neglected diseases. The company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development, the company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit www.spotlightinnovation.com.
Total Page Views: 1175
